Efficacy and Safety of Cannabidiol Oil in Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Trial

Phase 2

• Conditions: Psoriasis; Psoriasis, Chronic plaque type psoriasis

• Registration Number: TCTR20220622002
• Lead Sponsor: ational Research Council of Thailand (NRCT)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-22
• Study Completion: 2023-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: nknown
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Chronic plaque type psoriasis patients
- Age 18-80 years old
- No change of systemic treatment with in last 1 month

Exclusion Criteria

- Current biologic therapy
- Active psychiatric problem with in last 1 year
- Active hepatic or renal diseases
- Pregnancy or lactation
- Allergy to cannabidiol (CBD) or CBD derivatives

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of psoriasis at 12 weeks after end of the intervention Psoriasis Area Severity index

Secondary Outcome Measures

Name	Time	Method
Itching at 12 weeks after end of the intervention visual analog scale of itch,Quality of life at 12 weeks after end of the intervention Dermatology Life Quality Index ,Depression/anxiety/stress at 12 weeks after end of the intervention Depression anxiety stress scales,Sleep quality at 12 weeks after end of the intervention the Pittsburgh sleep quality index,Sleep efficiency at 12 weeks after end of the intervention Sleep efficiency percentage